Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

VTVT vTv Therapeutics Inc

-1.18 (-4.08%)
May 24 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 6,298
Bid Price 22.54
Ask Price 30.46
News -
Day High 28.84


52 Week Range


Day Low 27.5419
Company Name Stock Ticker Symbol Market Type
vTv Therapeutics Inc VTVT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.18 -4.08% 27.72 17:16:17
Open Price Low Price High Price Close Price Prev Close
28.84 27.5419 28.84 27.72 28.90
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
324 6,298 $ 28.13 $ 177,148 - 7.38 - 39.60
Last Trade Time Type Quantity Stock Price Currency
19:52:42 18 $ 27.98 USD

vTv Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
83.44M 3.01M - 0 -20.25M -6.73 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

vTv Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No VTVT Message Board. Create One! See More Posts on VTVT Message Board See More Message Board Posts

Historical VTVT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week27.8829.0125.5028.526,273-0.16-0.57%
1 Month25.8929.1922.500126.285,5281.837.07%
3 Months17.1730.9912.9521.2413,44710.5561.44%
6 Months10.5130.997.3815.6449,30517.21163.75%
1 Year38.55639.607.3824.19105,357-10.84-28.10%
3 Years98.80115.207.3859.61444,046-71.08-71.94%
5 Years70.00205.207.3898.15935,098-42.28-60.40%

vTv Therapeutics Description

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Your Recent History

Delayed Upgrade Clock